GURUFOCUS.COM » STOCK LIST » Industrials » Business Services » Thelma Therapeutics (XKRX:015540) » Definitions » Debt-to-Equity

Thelma Therapeutics (XKRX:015540) Debt-to-Equity : 1.09 (As of Sep. 2022)


View and export this data going back to 1989. Start your Free Trial

What is Thelma Therapeutics Debt-to-Equity?

Thelma Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was ₩11,479 Mil. Thelma Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was ₩0 Mil. Thelma Therapeutics's Total Stockholders Equity for the quarter that ended in Sep. 2022 was ₩10,535 Mil. Thelma Therapeutics's debt to equity for the quarter that ended in Sep. 2022 was 1.09.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Thelma Therapeutics's Debt-to-Equity or its related term are showing as below:

XKRX:015540's Debt-to-Equity is not ranked *
in the Business Services industry.
Industry Median: 0.385
* Ranked among companies with meaningful Debt-to-Equity only.

Thelma Therapeutics Debt-to-Equity Historical Data

The historical data trend for Thelma Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Thelma Therapeutics Debt-to-Equity Chart

Thelma Therapeutics Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.00 2.24 1.78 27.59 0.62

Thelma Therapeutics Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.94 0.62 0.72 0.98 1.09

Competitive Comparison of Thelma Therapeutics's Debt-to-Equity

For the Specialty Business Services subindustry, Thelma Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Thelma Therapeutics's Debt-to-Equity Distribution in the Business Services Industry

For the Business Services industry and Industrials sector, Thelma Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Thelma Therapeutics's Debt-to-Equity falls into.



Thelma Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Thelma Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2021 is calculated as

Thelma Therapeutics's Debt to Equity Ratio for the quarter that ended in Sep. 2022 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Thelma Therapeutics  (XKRX:015540) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Thelma Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Thelma Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Thelma Therapeutics (XKRX:015540) Business Description

Traded in Other Exchanges
N/A
Address
Mapo-gu, Seoul Sangam DMC Prugio City, 25, World Cup Buk-ro 54-gil, Seoul, KOR
Thelma Therapeutics, formerly Medipartner Biotechnology is a South Korean company engaged in providing hospital management support, dental material distribution, medical devices manufacturing, and development of new materials.

Thelma Therapeutics (XKRX:015540) Headlines

No Headlines